ライフサイエンスコーパス: bronchiolitis obliterans

1 the development of interstitial fibrosis and bronchiolitis obliterans.

2 after ECP in lung allograft recipients with bronchiolitis obliterans.

3 is include idiopathic pneumonia syndrome and bronchiolitis obliterans.

4 lung transplant might be an option to treat bronchiolitis obliterans.

5 istologically, the condition is often called bronchiolitis obliterans.

6 ssary to overcome the challenge presented by bronchiolitis obliterans.

7 hurdle to overcome in long-term survival is bronchiolitis obliterans.

8 roduction plant were reported to have severe bronchiolitis obliterans.

9 incidence of acute rejection; none developed bronchiolitis obliterans.

10 ure is small airway obstruction arising from bronchiolitis obliterans.

11 ssue fibrosis manifesting as scleroderma and bronchiolitis obliterans.

12 and pulmonary dysfunction characteristic of bronchiolitis obliterans.

13 cations included pulmonary fibrosis (3%) and bronchiolitis obliterans (3%).

14 The most common causes of late death were bronchiolitis obliterans (35/61, 57%), infection (13/61,

15 One-year survival was 77% for patients with bronchiolitis obliterans, 37% for patients with IPS, and

16 e bronchiolitis (obliterative bronchiolitis, bronchiolitis obliterans), acute bronchiolitis, diffuse

17 , is of limited accuracy in diagnosing early bronchiolitis obliterans after lung transplantation.

18 V is also associated with the development of bronchiolitis obliterans after transplantation, we deter

19 , IL-6 may play a role in the development of bronchiolitis obliterans after transplantation.

20 Asthma as well as bronchiolitis obliterans and chronic bronchitis are chro

21 d prognostic features distinguishing it from bronchiolitis obliterans and idiopathic pulmonary fibros

22 nchiolitis, cystic fibrosis, post-transplant bronchiolitis obliterans and more recently chronic obstr

23 use of the associations between diacetyl and bronchiolitis obliterans and other severe respiratory di

24 mia, more frequent disease, earlier onset of bronchiolitis obliterans and shorter survival.

25 follow-up might be helpful to better manage bronchiolitis obliterans and to detect and treat it earl

26 omplications, however, including infections, bronchiolitis obliterans, and complications of immunosup

27 in treating patients with panbronchiolitis, bronchiolitis obliterans, and rejection after lung trans

28 Idiopathic pneumonia syndrome (IPS) and bronchiolitis obliterans are now recognized as part of a

29 mouse model of multiorgan system injury with bronchiolitis obliterans associated with a robust GC rea

30 ive proportion of patients with fibrosis and bronchiolitis obliterans, at each successive scheduled s

31 brosis in lung and skin leads to progressive bronchiolitis obliterans (BO) and scleroderma, respectiv

32 Given the impact of T cells on bronchiolitis obliterans (BO) in lung transplantation, w

33 Bronchiolitis obliterans (BO) is a detrimental late pulm

34 Bronchiolitis obliterans (BO) is the pathologic manifest

35 g-term outcome of lung transplantation, with bronchiolitis obliterans (BO) representing the predomina

36 The pathogenesis of bronchiolitis obliterans (BO), a common and devastating

37 ed patient and graft survival, occurrence of bronchiolitis obliterans (BO), and episodes of rejection

38 a proposed mechanism driving posttransplant bronchiolitis obliterans (BO), and its clinical correlat

39 ultiorgan system disease model that includes bronchiolitis obliterans (BO), dependent upon GC B cells

40 chronic GVHD in a multiorgan system model of bronchiolitis obliterans (BO), driven by germinal center

41 tion and airway obliteration, which leads to bronchiolitis obliterans (BO), which is pathognomonic fo

42 ontribute to lymphocytic bronchitis (LB) and bronchiolitis obliterans (BO).

43 inically relevant murine model of cGVHD with bronchiolitis obliterans (BO).

44 esize that CMV viremia increases the risk of bronchiolitis obliterans (BOS) or death and retransplant

45 thelial and intraluminal fibrotic lesions of bronchiolitis obliterans by day 28.

46 indicate that they probably had occupational bronchiolitis obliterans caused by the inhalation of vol

47 llular rejection and with the development of bronchiolitis obliterans could not be confirmed in human

48 Therefore, earlier bronchiolitis obliterans detection and more timely imple

49 Bronchiolitis obliterans developed in 29% of patients wi

50 arget tissue that results in scleroderma and bronchiolitis obliterans, diagnostic features of cGVHD.

51 osttransplantation course was complicated by bronchiolitis obliterans from chronic rejection and by r

52 gressive disease; in contrast, patients with bronchiolitis obliterans from Stevens-Johnson syndrome o

53 Patients with postinfectious bronchiolitis obliterans generally have chronic, nonprog

54 t recipients with histopathologically proved bronchiolitis obliterans (group A) and 21 with normal bi

55 Experimental models of IPS and bronchiolitis obliterans have proven useful to test stra

56 s were identified to show histopathology for bronchiolitis obliterans in all allogeneic grafts.

57 The diagnosis of bronchiolitis obliterans in children can be made with co

58 tation, diagnosis, treatment, and outcome of bronchiolitis obliterans in the nontransplant, pediatric

59 f the lower incidence of acute rejection and bronchiolitis obliterans in younger versus older childre

60 WT APC normalized bronchiolitis obliterans-induced pulmonary dysfunction.

61 In a different cGVHD model, in which bronchiolitis obliterans is a prominent manifestation, F

62 Bronchiolitis obliterans is a rare form of chronic obstr

63 raft-versus-host disease (GVHD) and IPS, and bronchiolitis obliterans is pathognomonic of chronic GVH

64 Bronchiolitis obliterans is the leading cause of chronic

65 ance, Artificial Intelligence, Air Trapping, Bronchiolitis Obliterans, Lung Transplant Supplemental m

66 = 89), pulmonary vascular disease (n = 44), bronchiolitis obliterans (n = 21), pulmonary alveolar pr

67 istress syndrome (n=4), hemosiderosis (n=1), bronchiolitis obliterans (n=1), sarcoidosis (n=1), and b

68 n included pulmonary vascular disease (n=6), bronchiolitis obliterans (n=2), bronchopulmonary dysplas

69 , idiopathic pneumonia syndrome (IPS, n=19), bronchiolitis obliterans (n=22), and other uncommon synd

70 Bronchiolitis obliterans organizing pneumonia (BOOP) and

71 The peak prevalence of bronchiolitis obliterans organizing pneumonia (BOOP) and

72 Bronchiolitis obliterans organizing pneumonia (BOOP) has

73 ganizing diffuse alveolar damage (DAD) in 2, bronchiolitis obliterans organizing pneumonia (BOOP) in

74 Bronchiolitis obliterans organizing pneumonia (BOOP) is

75 Bronchiolitis obliterans organizing pneumonia (BOOP) is

76 interstitial pneumonia (AIP), bronchiolitis, bronchiolitis obliterans organizing pneumonia (BOOP), an

77 stic plugs within air spaces consistent with bronchiolitis obliterans organizing pneumonia (BOOP).

78 bronchiolitis obliterans syndrome (BOS), and bronchiolitis obliterans organizing pneumonia (BOOP).

79 acute respiratory distress syndrome (n = 2), bronchiolitis obliterans organizing pneumonia (n = 2), p

80 ungal dermatitis, oral herpetic lesions, and bronchiolitis obliterans organizing pneumonia after 2 ep

81 We report the case of a lady who developed bronchiolitis obliterans organizing pneumonia and erythe

82 Bronchiolitis obliterans organizing pneumonia and erythe

83 cryptogenic organizing pneumonia (idiopathic bronchiolitis obliterans organizing pneumonia), and pulm

84 interstitial pneumonia, and the seventh had bronchiolitis obliterans organizing pneumonia.

85 D that recapitulates pulmonary fibrosis from bronchiolitis obliterans, recipients of Tet2-deleted don

86 The pathomechanism of bronchiolitis obliterans remains unclear and it remains

87 antly elevated within 3 months of developing bronchiolitis obliterans syndrome (8.3 [1.4-25.1] vs. 3.

88 Thin-section CT studies in six patients with bronchiolitis obliterans syndrome (age range, 2 months t

89 with human cytomegalovirus increases risk of bronchiolitis obliterans syndrome (aHR, 2.88; 95% CI, 1.

90 In past years, a diagnosis of bronchiolitis obliterans syndrome (BOS) after allogeneic

91 emic steroids are the standard treatment for bronchiolitis obliterans syndrome (BOS) after allogeneic

92 genetic polymorphisms on the development of bronchiolitis obliterans syndrome (BOS) after lung trans

93 Bronchiolitis obliterans syndrome (BOS) after lung trans

94 Bronchiolitis obliterans syndrome (BOS) after lung trans

95 Using log-rank test, freedom from bronchiolitis obliterans syndrome (BOS) and graft surviv

96 the internationally recognized definition of bronchiolitis obliterans syndrome (BOS) and longer follo

97 for chronic graft dysfunction manifested as bronchiolitis obliterans syndrome (BOS) and worse posttr

98 Freedom from bronchiolitis obliterans syndrome (BOS) at three years w

99 mplications occur frequently post-HSCT, with bronchiolitis obliterans syndrome (BOS) being the most c

100 Bronchiolitis obliterans syndrome (BOS) cases had lower

101 Development of bronchiolitis obliterans syndrome (BOS) following lung t

102 unosuppressive therapy for the management of bronchiolitis obliterans syndrome (BOS) has been sparsel

103 d for multiorgan system cGVHD and associated bronchiolitis obliterans syndrome (BOS) in a murine mode

104 plant operation on survival and the onset of bronchiolitis obliterans syndrome (BOS) in consecutive l

105 rentiation is associated with development of bronchiolitis obliterans syndrome (BOS) in human lung al

106 after lung transplantation fails to prevent bronchiolitis obliterans syndrome (BOS) in many patients

107 lowing lung transplantation fails to prevent bronchiolitis obliterans syndrome (BOS) in many patients

108 The term bronchiolitis obliterans syndrome (BOS) is a clinical su

109 Bronchiolitis obliterans syndrome (BOS) is a condition o

110 Background: Bronchiolitis obliterans syndrome (BOS) is a late-onset

111 Bronchiolitis obliterans syndrome (BOS) is a major imped

112 Early diagnosis of bronchiolitis obliterans syndrome (BOS) is critical in u

113 Chronic allograft rejection manifested as bronchiolitis obliterans syndrome (BOS) is the leading c

114 Bronchiolitis obliterans syndrome (BOS) is the major lim

115 Bronchiolitis obliterans syndrome (BOS) is the major lim

116 Bronchiolitis obliterans syndrome (BOS) is the major obs

117 Bronchiolitis obliterans syndrome (BOS) is the most comm

118 Bronchiolitis obliterans syndrome (BOS) is the primary l

119 allograft dysfunction (CLAD), presenting as bronchiolitis obliterans syndrome (BOS) or restrictive a

120 ll lung transplant recipients suffering from bronchiolitis obliterans syndrome (BOS) or restrictive a

121 n (AR) and development of chronic rejection, bronchiolitis obliterans syndrome (BOS) remain major lim

122 Bronchiolitis obliterans syndrome (BOS) remains the lead

123 Bronchiolitis obliterans syndrome (BOS) remains the main

124 -obliteration of the allograft airway during bronchiolitis obliterans syndrome (BOS) that occurs afte

125 Bronchiolitis obliterans syndrome (BOS), a condition of

126 ement of six lung transplant recipients with bronchiolitis obliterans syndrome (BOS), a condition pre

127 s limited by infectious complications and by bronchiolitis obliterans syndrome (BOS), a form of chron

128 Bronchiolitis obliterans syndrome (BOS), a process of fi

129 w long-term survival and a high incidence of bronchiolitis obliterans syndrome (BOS), an inflammation

130 gnized, idiopathic pneumonia syndrome (IPS), bronchiolitis obliterans syndrome (BOS), and bronchiolit

131 ssion to chronic rejection that manifests as bronchiolitis obliterans syndrome (BOS), but no biomarke

132 tive (ELR(+)) CXC chemokines associated with bronchiolitis obliterans syndrome (BOS), but the effect

133 n after lung transplantation, manifesting as bronchiolitis obliterans syndrome (BOS), has become the

134 g to progressive airflow obstruction, termed bronchiolitis obliterans syndrome (BOS), is the major ca

135 man lung allograft rejection, represented by bronchiolitis obliterans syndrome (BOS), is the single m

136 ween these disorders and risk for subsequent bronchiolitis obliterans syndrome (BOS), mortality and g

137 Bronchiolitis obliterans syndrome (BOS), pathognomonic f

138 allograft dysfunction (CLAD), and especially bronchiolitis obliterans syndrome (BOS), remain dominant

139 Bronchiolitis obliterans syndrome (BOS), the clinical co

140 Bronchiolitis obliterans syndrome (BOS), the major cause

141 n the fibro-obliterative lesion found during bronchiolitis obliterans syndrome (BOS), we hypothesized

142 mputed tomography morphology, mortality, and bronchiolitis obliterans syndrome (BOS)-free survival we

143 e development of chronic rejection, known as bronchiolitis obliterans syndrome (BOS).

144 all airway injury would increase the risk of bronchiolitis obliterans syndrome (BOS).

145 tation and is an established risk factor for bronchiolitis obliterans syndrome (BOS).

146 al outcomes, often due to the development of bronchiolitis obliterans syndrome (BOS).

147 tation remains limited by the development of bronchiolitis obliterans syndrome (BOS).

148 ejection or infection) (NORMAL POST) or with bronchiolitis obliterans syndrome (BOS).

149 irreversible decline in lung function termed bronchiolitis obliterans syndrome (BOS).

150 mortality after lung transplantation (LT) is bronchiolitis obliterans syndrome (BOS).

151 to play an important role in the etiology of bronchiolitis obliterans syndrome (BOS).

152 hether it correlated with the development of bronchiolitis obliterans syndrome (BOS).

153 r lavage (BAL) fluid samples from LTxRs with bronchiolitis obliterans syndrome (BOS).

154 gnificant risk factor for the development of bronchiolitis obliterans syndrome (BOS).

155 r inhalation (L-CsA-i) for the prevention of bronchiolitis obliterans syndrome (BOS).

156 The primary endpoint was freedom from bronchiolitis obliterans syndrome (BOS).

157 obliterans (BO), and its clinical correlate bronchiolitis obliterans syndrome (BOS).

158 splantation may contribute to development of bronchiolitis obliterans syndrome (BOS).

159 al owing to chronic allograft failure termed bronchiolitis obliterans syndrome (BOS).

160 The per-protocol analysis shows incidence of bronchiolitis obliterans syndrome (BOS): 1/43 in the Eve

161 Secondary outcomes included freedom from bronchiolitis obliterans syndrome (fBOS) and rates of ac

162 o be important in obliterative bronchiolitis/bronchiolitis obliterans syndrome (OB/BOS), which severe

163 rvival (P = 0.09) and increased freedom from bronchiolitis obliterans syndrome (P = 0.03) was observe

164 sease (P=0.54) nor a subsequent diagnosis of bronchiolitis obliterans syndrome (P=0.70).

165 enting chronic rejection of lung allografts (bronchiolitis obliterans syndrome [BOS]) and proinflamma

166 ce of all other causes (currently defined as bronchiolitis obliterans syndrome [BOS]) is considered t

167 ar that patients may develop an obstructive (bronchiolitis obliterans syndrome [BOS]) or a restrictiv

168 A diagnosis of chronic rejection (bronchiolitis obliterans syndrome [BOS]) was made in 191

169 Different clinical phenotypes (bronchiolitis obliterans syndrome [BOS]-neutrophilic BOS

170 Infants and young children with bronchiolitis obliterans syndrome after lung transplanta

171 smatch model of multiorgan system cGVHD with bronchiolitis obliterans syndrome and a minor MHC mismat

172 study was to investigate the development of bronchiolitis obliterans syndrome and graft loss after L

173 onic lung allograft rejection in the form of bronchiolitis obliterans syndrome and its histopathologi

174 distinct obstructive and restrictive forms: bronchiolitis obliterans syndrome and restrictive allogr

175 term comprises 2 major clinical phenotypes: bronchiolitis obliterans syndrome and restrictive allogr

176 Because current literature suggests bronchiolitis obliterans syndrome and restrictive allogr

177 valuates the current diagnostic criteria for bronchiolitis obliterans syndrome and reviews the epidem

178 rom lung transplant recipients who developed bronchiolitis obliterans syndrome and were compared to s

179 Emphysema, female gender, and bronchiolitis obliterans syndrome are risk factors for s

180 odel demonstrated that the increased risk of bronchiolitis obliterans syndrome associated with primar

181 condary end points were overall survival and bronchiolitis obliterans syndrome at 2 years.

182 sinophilic BAL predisposed to development of bronchiolitis obliterans syndrome but particularly to re

183 d a shorter survival and an earlier onset of bronchiolitis obliterans syndrome compared with patients

184 pha as a potential new therapeutic target in bronchiolitis obliterans syndrome deserving of a randomi

185 This resembles bronchiolitis obliterans syndrome developed following hu

186 Adjustment for clinical variables including bronchiolitis obliterans syndrome did not change this re

187 aft-vs-host disease affects the lung tissue, bronchiolitis obliterans syndrome ensues.

188 A trend, however, toward reduced onset of bronchiolitis obliterans syndrome grade 2 or 3 was obser

189 survival in a multivariable model including bronchiolitis obliterans syndrome grade and baseline FEV

190 Patients with bronchiolitis obliterans syndrome had a higher risk of s

191 Bronchiolitis obliterans syndrome has been associated wi

192 o activate fibroblasts in the development of bronchiolitis obliterans syndrome has not been evaluated

193 enance macrolide therapy in the treatment of bronchiolitis obliterans syndrome in lung transplant rec

194 after heart transplantation, and potentially bronchiolitis obliterans syndrome in lung transplant rec

195 ges to the progress of medical management of bronchiolitis obliterans syndrome include difficulties a

196 tion is associated with an increased risk of bronchiolitis obliterans syndrome independent of acute r

197 Bronchiolitis obliterans syndrome is a fibrotic occlusio

198 Bronchiolitis obliterans syndrome is a major problem for

199 Bronchiolitis obliterans syndrome is caused by a fibropr

200 Bronchiolitis obliterans syndrome is characterized by fi

201 Bronchiolitis obliterans syndrome is the leading cause o

202 and were divided into three groups: no CLAD (bronchiolitis obliterans syndrome level 0 [BOS 0]), earl

203 Recent data suggest that bronchiolitis obliterans syndrome may affect up to 6% of

204 onic lung allograft dysfunction manifests as bronchiolitis obliterans syndrome or the recently descri

205 was not a risk factor for the development of bronchiolitis obliterans syndrome or worse overall survi

206 sions in explanted lungs from four end-stage bronchiolitis obliterans syndrome patients was analyzed

207 Importantly, the 2014 NIH-CC for bronchiolitis obliterans syndrome perform poorly in chil

208 Bronchiolitis obliterans syndrome remains the leading ca

209 trated that respiratory viral infection is a bronchiolitis obliterans syndrome risk factor and virus-

210 The remaining four patients had bronchiolitis obliterans syndrome scores of 0 compared w

211 Bronchiolitis Obliterans Syndrome seriously reduces long

212 iated with a significantly increased risk of bronchiolitis obliterans syndrome stage 1 (grade 1: rela

213 acute rejection, lymphocytic bronchitis, and bronchiolitis obliterans syndrome stage 1, using univari

214 Freedom from bronchiolitis obliterans syndrome was lower, and mortali

215 the association of bronchial dilatation with bronchiolitis obliterans syndrome was significant (P = .

216 s in the six patients with clinically proved bronchiolitis obliterans syndrome were mosaic perfusion

217 Small airway fibrosis (bronchiolitis obliterans syndrome) is the primary obstac

218 genesis of chronic lung allograft rejection (bronchiolitis obliterans syndrome) remains to be elucida

219 Of the 22 patients (5%) who experienced bronchiolitis obliterans syndrome, 15 (6%) were in the a

220 Bronchiolitis obliterans syndrome, a common form of chro

221 epatitis C viral RNA (HCV RNA), freedom from bronchiolitis obliterans syndrome, acute rejection, and

222 reported risk factor for the development of bronchiolitis obliterans syndrome, an important cause of

223 e hypertension, renal dysfunction, diabetes, bronchiolitis obliterans syndrome, and malignancy.

224 nd the first 6 months, bacterial infections, bronchiolitis obliterans syndrome, and survival.

225 tervention in five patients with progressive bronchiolitis obliterans syndrome, anti-TNFalpha treatme

226 transplants is limited by chronic rejection (bronchiolitis obliterans syndrome, BOS).

227 , 41 patients remained STA, and 37 had CLAD (bronchiolitis obliterans syndrome, BOS, [n = 32] or rest

228 s that CMVIG prophylaxis reduces the risk of bronchiolitis obliterans syndrome, but a controlled tria

229 Acute rejection is a major risk factor for bronchiolitis obliterans syndrome, but noninvasive bioma

230 TF4 axis in the altered airway epithelium of bronchiolitis obliterans syndrome, including substantial

231 ) chronic allograft dysfunction, manifest by bronchiolitis obliterans syndrome, is frequent and limit

232 Unlike bronchiolitis obliterans syndrome, it is not universally

233 sponse to viruses and in the pathogenesis of bronchiolitis obliterans syndrome, the predominant manif

234 hown to be implicated in the pathogenesis of bronchiolitis obliterans syndrome, which is considered t

235 Among lung transplant recipients, "bronchiolitis obliterans syndrome," a disorder with clin

236 nd 30-day mortality, follow-up survival, and bronchiolitis obliterans syndrome-free survival.

237 lantation imitate the in vivo development of bronchiolitis obliterans syndrome-like lesions and revea

238 th chronic lung allograft rejection known as bronchiolitis obliterans syndrome.

239 he surviving study subjects remain free from bronchiolitis obliterans syndrome.

240 d the impact of primary graft dysfunction on bronchiolitis obliterans syndrome.

241 gnificant risk factor for the development of bronchiolitis obliterans syndrome.

242 rences were observed in the overall onset of bronchiolitis obliterans syndrome.

243 reduce the incidence of post-lung transplant bronchiolitis obliterans syndrome.

244 recipients is limited by the development of bronchiolitis obliterans syndrome.

245 y may improve lung function in patients with bronchiolitis obliterans syndrome.

246 the main risk factor for the development of bronchiolitis obliterans syndrome.

247 ection has been linked to the development of bronchiolitis obliterans syndrome.

248 fts due to acute rejection (AR) or developed bronchiolitis obliterans syndrome.

249 defined as idiopathic pneumonia syndrome or bronchiolitis obliterans syndrome.

250 Four patients developed bronchiolitis obliterans syndrome.

251 ociated with an increased risk of developing bronchiolitis obliterans syndrome.

252 n of epithelial to mesenchymal transition in bronchiolitis obliterans syndrome.

253 ortality after lung transplantation (LTX) is bronchiolitis obliterans syndrome.

254 ng transplant patients prior to diagnosis of bronchiolitis obliterans syndrome.

255 hromycin, and montelukast should be used for bronchiolitis obliterans syndrome; and the addition of n

256 ted rejection, acute cellular rejection, and bronchiolitis obliterans syndrome; however, the signific

257 ces epithelial injury via TGF-beta in murine bronchiolitis obliterans; that TGF-beta and the C' casca

258 occur and increase the chance of developing bronchiolitis obliterans; therefore, many centers perfor

259 11 years), the overall rate of occurrence of bronchiolitis obliterans was 46% (80/175) and the overal

260 Major risk factors for the development of bronchiolitis obliterans were age older than 3 years, mo

261 nced bronchus-associated lymphoid tissue and bronchiolitis obliterans were unique for the immunizing

262 rgan system, nonsclerodermatous disease with bronchiolitis obliterans where cGVHD is dependent on ant

263 The major late complication was bronchiolitis obliterans, which occurred in 27% of patie

264 Bronchiolitis obliterans with organizing pneumonia (BOOP

265 c encepatholopathy and pulmonary findings of bronchiolitis obliterans with organizing pneumonia (BOOP